General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Amgen(SIGNIFICANT), Merck & Co., Inc.(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(SIGNIFICANT), Urovant Pharmaceuticals(MODEST), PhamaIN(SIGNIFICANT), AstraZeneca Pharmaceuticals(SIGNIFICANT), CSL Vifor(SIGNIFICANT), Sanofi(SIGNIFICANT), Cytokinetics(SIGNIFICANT), Roche Diagnostics(SIGNIFICANT), Tricog Health(SIGNIFICANT), Lexicon(SIGNIFICANT), Bayer Healthcare Pharmaceuticals(SIGNIFICANT), scPharmaceuticals(SIGNIFICANT), Otsuka Pharmaceutical Co.(SIGNIFICANT), Novo Nordisk Inc.(SIGNIFICANT), Corcept Therapeutics(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Bristol-Myers Squibb(NONE), AstraZeneca Pharmaceuticals(NONE), Novartis Corporation(SIGNIFICANT), Pfizer(SIGNIFICANT), Bristol-Myers Squibb Company (SIGNIFICANT), Novartis Corporation(SIGNIFICANT)

View Full Disclosure